Who Paid My Doc
Ph I Pk multitumor SubQ formulation Relatlimab
Research payments
$823,840
Through program year 2024, $823,840 in research payments was reported against Ph I Pk multitumor SubQ formulation Relatlimab, across 14 payments, paid by E.R. Squibb & Sons, L.L.C..
- Paid by
- E.R. Squibb & Sons, L.L.C.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $3,259 | 3 |
| 2023 | Research | $202,152 | 6 |
| 2022 | Research | $26,849 | 3 |
| 2021 | Research | $133,877 | 1 |
| 2020 | Research | $457,703 | 1 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
1 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.